Co-Diagnostics Secures Australian Patent for PCR Testing Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Source: PRnewswire
- Patent Protection Strengthened: Co-Diagnostics has been granted Australian Patent No. AU2022270084A1, marking the first patent for its novel Co-Dx PCR platform, which enhances the company's intellectual property in nucleic acid detection and analysis, thereby boosting its market competitiveness.
- Market Potential Enhanced: The patent specifically covers the design and operation of the Co-Dx PCR Pro™ instrument and test cups, aimed at facilitating high-quality PCR testing outside traditional laboratory settings to meet the growing market demand.
- Strategic Positioning: Following a record-breaking flu season in Australia, the patent grant provides strategic protection for Co-Dx's potential commercial partners to introduce or distribute the platform in the region, safeguarding its commercial potential.
- Technological Innovation: The Co-Dx PCR platform leverages patented Co-Primers® technology to deliver rapid, sensitive, and specific molecular diagnostics, promoting widespread applications in infectious disease testing and further solidifying the company's leadership in the molecular diagnostics field.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
